Harry Thomasian Jr.
Known title: Chief Financial OfficerCIK: 0001886301
Harry Thomasian Jr.'s purchase track record
How the stock did after each of Harry Thomasian Jr.'s open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since November 26, 2021
Stock higher 6 months later
25%
3 months: 25%
Median 6-month return
-27.3%
3 months: -17.4%
Beat the S&P 500
25%
median -32.0% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/25/2025 | PGEN | $40K | +19.2% | +11.5% | -1.9% |
| 1/27/2023 | PGEN | $50K | -26.2% | -15.8% | +12.6% |
| 8/23/2022 | PGEN | $51K | -8.5% | -38.7% | -3.2% |
| 11/26/2021 | PGEN | $101K | -42.8% | -64.3% | -9.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PGEN | ▲ Buy | Option Exercise | 10,744 | $51K | 9/23/2026 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 42,918 | $100K | 9/23/2026 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 2 | $2 | 9/23/2026 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 1 | $1 | 9/23/2026 | View on chart |
| PGEN | ▼ Sell | Tax Withholding | 3,577 | $26K | 8/23/2026 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 7,291 | — | 8/23/2026 | View on chart |
| PGEN | ▼ Sell | Open Market | 100,000 | $606K | 7/31/2026 | View on chart |
| PGEN | ▼ Sell | Open Market | 171,429 | $948K | 7/1/2026 | View on chart |
| PGEN | ▼ Sell | Open Market | 28,571 | $165K | 6/29/2026 | View on chart |
| PGEN | ▼ Sell | Open Market | 41,884 | $183K | 5/28/2026 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 87,500 | — | 5/23/2026 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 40,293 | — | 3/18/2026 | View on chart |
| PGEN | ▲ Buy | Open Market | 2,932 | $10K | 9/26/2025 | View on chart |
| PGEN | ▲ Buy | Open Market | 8,284 | $30K | 9/25/2025 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 154,475 | — | 5/16/2025 | View on chart |
| PGEN | ▼ Sell | Tax Withholding | 51,441 | $75K | 5/16/2025 | View on chart |
| PGEN | ▲ Buy | Grant | 125,000 | $0 | 1/29/2025 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 135,714 | — | 4/5/2024 | View on chart |
| PGEN | ▼ Sell | Tax Withholding | 67,389 | $94K | 4/5/2024 | View on chart |
| PGEN | ▼ Sell | Open Market | 9,045 | $15K | 8/24/2023 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 17,934 | — | 8/23/2023 | View on chart |
| PGEN | ▼ Sell | Open Market | 8,893 | $14K | 8/17/2023 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 17,934 | — | 8/16/2023 | View on chart |
| PGEN | ▼ Sell | Open Market | 6,852 | $8K | 8/10/2023 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 17,934 | — | 8/9/2023 | View on chart |
| PGEN | ▼ Sell | Open Market | 6,724 | $8K | 8/3/2023 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 17,934 | — | 8/2/2023 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 35,868 | — | 3/24/2023 | View on chart |
| PGEN | ▲ Buy | Open Market | 28,571 | $50K | 1/27/2023 | View on chart |
| PGEN | ▲ Buy | Open Market | 24,500 | $51K | 8/23/2022 | View on chart |
| PGEN | ▼ Sell | Open Market | 2,719 | $3K | 5/17/2022 | View on chart |
| PGEN | ▲ Buy | Option Exercise | 8,109 | — | 5/16/2022 | View on chart |
| PGEN | ▲ Buy | Open Market | 13,400 | $51K | 11/26/2021 | View on chart |
| PGEN | ▲ Buy | Open Market | 13,100 | $50K | 11/26/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Precigen mentioned in Zacks analyst blog
Precigen was highlighted in a Zacks analyst blog alongside other companies. The stock has risen more than 50% over the last three months, moving within its 52-week range of $2.99 to $8.98. Analysts currently have an average price target of $13.65 for the shares.
Precigen mentioned in Zacks analyst blog. Precigen was highlighted in a Zacks analyst blog alongside other companies. The stock has risen more than 50% over the last three months, moving within its 52-week range of $2.99 to $8.98. Analysts currently have an average price target of $13.65 for the shares.